News 14.12.18

Chemist Freek van Cauter: ‘We make molecules here’

At NTRC, chemists and biologists work closely together to develop new drugs, particularly against cancer and Parkinson's disease. Chemist Freek van Cauter gives us a look behind the scenes.

Read more
News 13.12.18

A cup of coffee with … Roxana Nicolae

This is Roxana Nicolae, originally from Romania and now working for BioConnection at Pivot Park.

Read more
News 10.12.18

Welcome Absano, Sublin and Agidens

Three new companies Absano, Sublin and Agidens have signed a contract with Pivot Park. Absano is a spin-off company of Modiquest. Sublin is a spin-off company of Nanoserve. Agidens contribute to the safety of the consumer and patient thanks to their experience in automation and in Life Sciences.

Read more
News 22.11.18

The road to funding

The Funding Event took place at Pivot Park. Start-ups and scale-ups had the opportunity to talk to invited investors.

Read more
News 22.11.18

Press release: NTRC launches the first HTS Assay for Arginase-1 inhibitors at ENA2018 Copy

NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018. Arginase-1 (Arg-1) is an important drug target for cancer immunotherapy.

Read more
News 10.11.18

Get this presentation about uHTS Copy

SLAS (Society for Laboratory Automation and Screening) visited Europe and the Pivot Park Screening Centre in June this year. During...

Read more
News 05.11.18

New predictive drug response biomarkers for approved kinase inhibitors

Press release, Oss, November, 02, 2018 Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new...

Read more
News 18.10.18

Funding Event 2018

We believe in connecting the right people to the right knowledge. Therefore, we organize the Funding Event on November 15th....

Read more
News 04.10.18

Community Meeting

On September 27th, the community meeting took place. We discussed about several topics. Attached the presentation. If you have any questions...

Read more